Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX – Get Free Report) was the recipient of a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 364,200 shares, an increase of 398.9% from the August 15th total of 73,000 shares. Based on an average daily trading volume, of 380,200 shares, the short-interest ratio is presently 1.0 days. Approximately 5.4% of the company’s stock are short sold.
Wall Street Analyst Weigh In
Separately, HC Wainwright reiterated a “buy” rating on shares of Kiora Pharmaceuticals in a research note on Thursday, August 24th.
Kiora Pharmaceuticals Price Performance
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of KPRX. Boothbay Fund Management LLC acquired a new position in Kiora Pharmaceuticals during the fourth quarter worth about $40,000. Dimensional Fund Advisors LP purchased a new position in Kiora Pharmaceuticals in the 1st quarter worth approximately $41,000. Acadian Asset Management LLC acquired a new position in shares of Kiora Pharmaceuticals during the 1st quarter worth approximately $70,000. Renaissance Technologies LLC acquired a new position in shares of Kiora Pharmaceuticals during the 1st quarter worth approximately $58,000. Finally, Walleye Capital LLC purchased a new stake in shares of Kiora Pharmaceuticals in the second quarter valued at approximately $162,000. Institutional investors and hedge funds own 13.92% of the company’s stock.
Kiora Pharmaceuticals Company Profile
Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.
- Five stocks we like better than Kiora Pharmaceuticals
- Dividend Tax Calculator
- Institutions and Insiders Are Gobbling Up Shares of HASI
- How to Invest in Cybersecurity
- Investors Betting On Triple-Digit Sales Growth At Las Vegas Sands
- Insider Trading – What You Need to Know
- 3 Reasons Why AMD Might Breakout Higher
Receive News & Ratings for Kiora Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiora Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.